A Subset of Patients Develops Off-Target Mechanisms of Resistance to TRK Inhibition
Resistance mediated by genomic alterations implicated in the MAPK pathway described
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
FDA Approves Fedratinib for Myelofibrosis
Evidence for efficacy is based on results from the JAKARTA study
FDA Approves Entrectinib for the Treatment of NTRK Fusion-Positive Solid Tumours in Adult and Adolescent Patients
It also approvesentrectinibfor the treatment of ROS1-positive metastatic NSCLC in adults
Communication Between AYA Cancer Patients and Healthcare Professionals Through Digital Media: Handle With Care!
Social media platforms provide the opportunity for virtual dialogue between patients and caregivers
Genomic Medicine Transforms Healthcare
Building evidence for genomic sequencing
FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumour
It is the first systemic therapy approved for patients with this tumour
Robust Evidence Supports Off-label Recommendations in the NCCN Guidelines
An in-depth re-analysis of recommendations beyond the FDA-approved indications
Names of Liposomal Medicines To Be Changed to Avoid Medication Errors
EU regulatory initiative aims to make a clearer distinction between liposomal and non-liposomal formulations of the same active substance
FDA Approves Darolutamide for Non-metastatic Castration-resistant Prostate Cancer
Approval is based on evidence from the ARAMIS study
FDA Approves Pembrolizumab for Advanced Oesophageal Squamous Cell Cancer
FDA also approved a new use for the PD-L1 IHC 22C3 pharmDx kit as a companion diagnostic
T Cell Response to Immune Checkpoint Blockade Characterised
T cell clones that may have just recently entered the tumour may be a cause for T cell response to immune checkpoint inhibitors
EMA Recommends Refusal of a Change to the Marketing Authorisation for Eltrombopag
The change concerned an extension of indications to previously untreated patients with severe aplastic anaemia from 2 years of age